This Down-on-Its-Luck Biotech Could Surge 150%, Wall Street Says. Should You Buy the Stock?
(NASDAQ: NVAX) shares have brought investors extremely good times and extremely bad times. They soared back in 2020 on hopes the biotech would score a win with its coronavirus vaccine candidate. But as Novavax fell behind in the race, the stock retreated.
Since then, Novavax has launched a vaccine, but the late-to-market entry meant it missed out on the biggest revenue opportunity. After all, vaccine demand is on the decline as we head toward a post-pandemic situation.
But that isn't holding back Wall Street's optimism about Novavax's stock performance potential. The average analyst forecast calls for a 150% increase over the coming 12 months.
Source Fool.com
Novavax Inc. Stock
€11.31
-25.340%
Our community is currently high on Novavax Inc. with 4 Buy predictions and 1 Sell predictions.
With a target price of 22 € there is a hugely positive potential of 94.52% for Novavax Inc. compared to the current price of 11.31 €.
